Haemonetics Jumps 17% as CSL Plasma Plans Full U.S. NexSys Rollout by 2027

HAE shares closed about 17.5% higher on October 8, 2026, after CSL Plasma said it expects to complete a rollout of Haemonetics' NexSys PCS plasma collection devices, with Persona PLUS technology and related disposables, across all of its U.S. plasma collection centers by the end of calendar 2027. The stock was up more than 17% before the open, traded about 12% higher in the morning and set a new 52-week high.

The update widens a supply agreement signed on August 18 that originally covered only a portion of CSL's U.S. centers, with no fixed timetable. The agreement is still non-exclusive and carries no minimum purchase commitments, and Haemonetics said the scope and timing of the rollout remain subject to change. For scale, the U.S. CSL business contributed about $155 million of Haemonetics revenue in fiscal 2024, before CSL moved away from its devices.

BTIG raised its price target to $130 from $110 and kept a Buy rating, lifting the multiple it applies to about 21 times earnings from 18.5 times, though it is not yet building any revenue from the new agreement into its forecasts. Haemonetics did not update its fiscal 2027 guidance and said it will discuss the financial impact on its fiscal second-quarter call in November, which BTIG expects on November 5. No new quarterly results were released on October 8; the most recent report covered the fiscal first quarter in August.

The next test is how much revenue Haemonetics attaches to the rollout in November, and whether CSL's deployment at its centers keeps to the 2027 timeline. After the jump, Yahoo Finance put the stock at about 21 times forward earnings versus a five-year average of 19.1 times, so the rerating already assumes a large part of the CSL volume returns.